Pacific Bio (PACB) Misses Q4 EPS by 2c

Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $36 million versus the consensus estimate of $36.12 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• FDA clears PM’s Zyn to market as lower cancer risk than cigarettes in 20 variants
• TSMC targets 2029 for panel-level CoPoS packaging in AI chip push - DigiTimes